Dossier assessment
Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Maintenance treatment of adult patients with platinumsensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy
Exclusively negative effects mainly due to different side effects, but no informative results on overall survival. Hence, added benefit not proven.
Project details
- Project no.
- A19-23
- Commission
- Commission awarded on 26.02.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-06-03.
Connected Projects
-
Dossier assessment
Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed